New drug could shrink eye tumors, saving sight
NCT ID NCT06414590
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called tebentafusp in 19 people with a rare eye cancer (uveal melanoma) that is too large to remove without taking the whole eye. The goal is to see if the drug can shrink the tumor by at least 20% so that less invasive surgery might be possible. Participants receive the drug before any other treatment and will have biopsies to check the effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED UNRESECTABLE UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
Wills Eye Hospital
ACTIVE_NOT_RECRUITINGPhiladelphia, Pennsylvania, 19107, United States